Condition: Cirrhosis, Liver · Liver Fibrosis · Ascites Hepatic · Sponsor: PharmaIN
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.
This description comes directly from the study's public registry record.
Cynthia C Jones · 206-568-1450 · PHIN.214001@pharmain.com
Always discuss trial participation with your own doctor first.
| Arizona Liver Health | Chandler, Arizona, United States | Recruiting |
| Southern California Research Center | Coronado, California, United States | Recruiting |
| Tandem Clinical Research | Marrero, Louisiana, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Methodist Health System, Dallas Medical Center | Dallas, Texas, United States | Recruiting |
| VA North Texas Healthcare System | Dallas, Texas, United States | Recruiting |
| Texas Liver Institute | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05490888